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ABSTRACT
Objectives: Several methodological problems arise when health outcomes
and resource utilization are collected at different sites. To avoid misleading
conclusions in multi-center economic evaluations the center effect needs to
be taken into adequate consideration. The aim of this article is to compare
several models, which make use of a different amount of information
about the enrolling center.
Methods: To model the association of total medical costs with the levels of
two sets of covariates, one at patient and one at center level, we considered
four statistical models, based on the Gamma model in the class of the
Generalized Linear Models with a log link, which use different amount of
information on the enrolling centers. Models were applied to Cost of
Strategies after Myocardial Infarction data, an international randomized
trial on costs of uncomplicated acute myocardial infarction (AMI).
Results: The simple center effect adjustment based on a single random
effect results in a more conservative estimation of the parameters as
compared with approaches which make use of deeper information on the
centers characteristics.
Conclusions: This study shows, with reference to a real multicenter trial,
that center information cannot be neglected and should be collected and
inserted in the analysis, better in combination with one or more random
effect, taking into account in this way also the heterogeneity among
centers because of unobserved centers characteristics.
Keywords: costs and cost analysis, Generalized Linear Models, multicenter
studies, myocardial infarction.
Introduction
Preparation of an economic evaluation in conjunction with the
analysis of a clinical trial has become a common practice, because
of the challenging opportunity of catching patient-speciﬁc data on
costs and outcomes. In order to assemble large sample sizes in a
short period and to improve results,multicenter studies are carried
out, often at international level. When health outcomes and
resource utilization are collected in several sites, numerous meth-
odological problems arise. A correlation in costs and outcomes
between patients recruited in particular centers may be expected,
given that centers often differ in clinical practice and patient
case-mix. Indeed, patients in the same center undergo a set of
center-speciﬁc treatment practices and evaluation of endpoints,
with perhaps a unique pattern of communications among the
patients within the given center. As a consequence, besides hetero-
geneity in the clinical factors (between-patient variability), analy-
sis should appropriately address the heterogeneity among centers
(between-hospital variability) [1]. This implies that outcomes of
patients within a hospital are generally more correlated with each
other than with patients from other hospitals: this is the so-called
cluster effect in the correlated data modeling literature, where
indeed the hospital is the cluster. Patients within a given hospital
may share characteristics (a speciﬁc disease, a sociodemographic
subgroup, the impact of hospital, physicians, and process-related
characteristics), and their outcomes are unlikely to be truly inde-
pendent of one another [2]. Still, heterogeneity across centers may
be particularly apparent when centers come from different coun-
tries [3]. A strict protocol, with a close speciﬁcation of a set of
sensitive inclusion/exclusion criteria, can reduce heterogeneity of
patients and limit the impact of confounding factors, allowing
outcome results to be pooled. The same cannot always be said for
costs. Indeed, main differences in costs can be attributable also
to the center-speciﬁc characteristics, where organizational and
managerial aspects play a major role. Differences in practice
patterns, use of resources, and costs between centers can shape the
economic impact of the treatment [4].
To avoid misleading conclusions in multi-center economic
evaluations the center effect needs to be appropriately consid-
ered. False inference can be drawn ignoring the structure of the
data and the crude difference in costs between centers may indeed
provide an unrealistic indication of the true differences between
them [5]. Several approaches have thus been attempted to deal
with such phenomenon, ranging from the very ﬁrst studies
relying upon ordinary least squares (OLS) models [6–9], up
to more recent contributions based on multi-level modeling
approaches [1,5,10] and more complex distributional assump-
tions [10], where the assumption of independence among obser-
vation is relaxed. In this context of correlated observations,
Grieve et al. [10] showed that multilevel Gamma models, are
more appropriate than OLS for assessing cost determinants. The
lower bias and more precise estimates provided by the Gamma
models as compared with OLS and other estimators, like the Cox
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proportional hazard estimator, were basically due to the capabil-
ity of the Gamma models to handle skewed data more appropri-
ately [11], releasing the assumptions of symmetry typical of the
OLS model based on the Normal distribution.
All these models, nevertheless, treat the center effect in terms
of a random effect, which is basically a latent variable mimicking
the center effect, for which usually no speciﬁc information is
collected at the time of study conduction and, consequently,
neglected at the analysis stage.
Thus, even though several methods are available for adjusting
for the center effect, and their pros and cons have been widely
discussed [12], few indications are available in the literature of
whether and to what extent the additional information gathered
for the characterization of the center is worth the effort.
The aim of this article is to compare several models, which
make use of a different amount of information about the enroll-
ing center, to understand and eventually to provide some guid-
ance on how useful it is to consider and collect center-speciﬁc
variables in the analysis. Such aspects are explored with reference
to Cost of Strategies after Myocardial Infarction (COSTAMI), an
international randomized trial on costs of uncomplicated AMI.
Materials and Methods
Statistical Models
Tomodel the association of total medical costs to levels of two sets
of covariates, one at patient and one at center level, we considered
four statistical models, all based on the Gamma distribution
(Generalized Linear Models) with a log link, known to have a
good ﬁt of positively skewed data, as the cost data often are [11].
Beside the Gamma model a wide set of alternative choices have
been proposed, from very simple ones like the log-normal [13] up
to more complex models in a fully Bayesian setting [14]. Never-
theless, among the models which are most easily handled by
common statistical packages, the Gamma has been shown, in
situationwithout center effects, to be a ﬂexible and perhaps robust
alternative in modeling cost distribution.
A Gamma regression model takes the form of:
C xi i i i= + + ( )β β ε ε σ0 20∼ Gamma , (1)
Where, Ci is the continuous outcome, the cost, for the i-th
patients; xi is a vector of values for a set of explanatory variables
related to the clinical characteristics of the subject, with associ-
ated a vector of slope coefﬁcients b. The coefﬁcient b0 is the
intercept of the model; ei is a random error term which represents
the unexplained variability between patients and is assumed to be
distributed as a Gamma with a mean of 0 and variance s2.
In all the versions of the Gamma model we considered, E
(C/x) is assumed to exhibits an exponential conditional mean or
log-link relationship, i.e., a log-link function [15] for the mean of
C given the covariates x:
E C x x( ) = ( )exp β
In the standard version of the model, where all observations
are treated as independent, the hierarchical structure of the data
is not revealed: all the patients have the same intercept and slope
coefﬁcients, no one variable related to the center characteristics
was considered, and ei is the only component of the total unex-
plained variability.
When the hierarchical structure of the data is taken into
account, e.g., in a multilevel model framework, the way the
unexplained variation is modeled changes drastically. In the most
basic multi-level model, the so-called random intercept model,
the subscript i for the patients and j for the centers, may be
written as:
C xij j i ij ij
j
= +( ) + + ( )
( )
β β ε ε σ
τ
0 u Gamma 0,
u Normal 0,
2
2
∼
∼ (2)
This model includes an additional term, uj, which represents
the unexplained variation between centers and indicates the
random effect of the center on the outcome variable. The random
variable uj applies to the patients in center j and is commonly
assumed to be distributed as a Normal with zero mean and
constant variance t2 that represents the residual variability
between centers not explained by the covariates. The residual
term eij is now a random error term representing the unexplained
variation for patients within a center. The intercept for the j-th
center (previously given as b0) is now given as the ﬁxed quantity
b0 plus the random component uj.
If covariates are available to describe center characteristics, it
may be appropriate to include this information in the analysis.
One possibility is to include a center-level explanatory variable
(or a set of them):
C x zij i j ij ij= + + + ( )β β γ ε ε σ0 ∼ Gamma 0, 2 (3)
The center-level covariate zj, and consequently the associated
slope coefﬁcient g, necessarily take the same value for all patients
in a particular center. The center characteristics are thus included
in the model as ﬁxed effects.
Another possibility, providing information on center charac-
teristics is available, is to adapt a multi-level Gamma model with
random intercept to this last model, which is nothing but the
development of the model (2) including additional explanatory
variables at the level of the centers:
C x zij i j j ij ij
j
= + + + + ( )
( )
β β γ ε ε σ
τ
0 u Gamma 0,
u Normal 0,
2
2
∼
∼ (4)
The variance term t2 represents the residual variability
between centers which is not explained by the covariates inserted
both at patient and at center level.
The COSTAMI Trial
Between January 1998 and August 2000, 458 patients with a
recent uncomplicated myocardial infarction from 10 centers (8 in
Italy and 2 in Turkey) were recruited and randomly assigned to
early discharge or usual care strategy.
Data were collected within a prospective randomized multi-
center trial [16]. The trial [16] compared early discharge strategy,
consisting of early (day 3 up to day 5 in case of organizational
problems) use of pharmacological stress echocardiography and
immediate subsequent discharge in case of a negative result of
test (Strategy 1), with usual care strategy, based on clinical evalu-
ation with no stress before discharge (that was on day 7–9) and
a symptom limited exercise electrocardiography (ECG) at 2–3
weeks after discharge (Strategy 2), according to present guide-
lines [17].
Data were collected on patient characteristics, AMI severity
measures, prescribed medications, and center characteristics.
Total medical costs per patient were measured as the sum of initial
hospital costs and follow-up hospital and outpatients costs at year
1. In the analysis we used National Health System reimbursement
tariffs from the site of the coordinating center, in the Friuli Venezia
Giulia Region, for costing resources calculated in each center. The
use of resources was calculated considering direct medical costs of
hospitalizations, investigations, and interventions and quantiﬁed
using the mean reimbursement for the Diagnosis-Related Group
and outpatient procedures.
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Clinical characteristics of the patients according to the center
and their structural characteristics are described in the supple-
mentary materials (Tables 1–3).
Statistical Analysis
The same set of variables was considered, when applicable, for
all four models (1–4), including: demographic characteristics,
clinical characteristics of the patients, the strategy of treatment,
and in the models (3) and (4) an additional set of center level
variables for the COSTAMI study pooled together. Inﬂuence of
center on the marginal estimates for models (1) and (4) were
computed using the Preisser and Qaqish inﬂuence measure [18],
indicating the effect that removing the given center has on the
ﬁnal effect estimates. This takes into account the leverage and
residuals in a set of observations to determine their inﬂuence on
regression parameter estimates and ﬁtted values. Missing values
of each variable inserted in the models were removed losing a
total of two observations. Variables were included in the analysis
on the basis of an informal clinical reasoning with the study
investigators on being associated with treatment costs: regarding
the clinical characteristics strategy, gender, age, presence of
diabetes, and/or hypertension, previous occurrence of AMI and
regarding center-related variables coronary angioplasty unit,
number of myocardial infarctions, and beds in cardiology. All
variables were inserted in the models and the AIC criterion was
computed in order to evaluate ﬁt of the models. Although the
main hypothesis in the COSTAMI trial was the reduction in costs
of the early discharge strategy (1) as compared with the standard
one (2), all P-values were computed as two-sided, obtaining in
this way more conservative estimates of the signiﬁcance of the
effects. Conﬁdence intervals for the intracenter correlation have
been obtained using a nonparametric Bootstrap (1000 runs).
All analyses have been performed using the R system [19]; the
models have been ﬁtted using the mlmRev [20] libraries. In
addition, results have been compared with the STATA statistical
software [21], estimates, ending up being very similar.
Results
The distribution of total costs according to the center character-
istics is shown in Table 1. Missing data incidence in the variables
used for modeling purposes was negligible: for patient character-
istics on average less than 0.1% of data had a loss of information
and for center characteristics all the data were available.
Median patient cost seems directly associated to the number
of hospitalizations, possibly because of a larger dimension and a
more complex organizational structure. On the other hand, the
other hospital characteristics result inversely associated with the
observed costs, as a consequence of economies of scale because of
the better utilization of available resources and to the major
expertise of specialized hospitals.
Median cost varies among centers from 2560€ per patient
up to the maximum of 4967€. Strategy 1 shows a lower median
cost than usual care strategy, because of anticipated discharge.
Fit for models without any center-speciﬁc covariate, (1) and (2),
is presented in Table 2. Simple center effect adjustment based on
a single random effect results in a more marked estimate of the
effect of strategy of patient management. In particular, signiﬁ-
cance of the parameters changes from -0.14 to -0.17 for
Strategy 1. Signiﬁcance of patient management strategy is
revised downward adding center information both as ﬁxed and
as random terms, i.e., as in models (3) and (4) (details shown in
Table 3). Inﬂuence of the unobserved center characteristics is
shown in Figure 1. Each point represents the effect on the
residual that each center has in the model. Thus, the greater the
value of the inﬂuence measure (y-axis), the greater the absolute
inﬂuence that the center has in the given model. Model M4 has
thus an overall maximum inﬂuence of 0.53 (Center 8) whereas
the M1 model has a maximum inﬂuence of 0.17 (Center 7),
about three times lower. Notice that incorporating the informa-
tion on center characteristics highlights the effect of just one
center, leaving the inﬂuence of the others at the same level as
without considering such information. Country effect is almost
negligible, as indicated by an analysis of the inﬂuence measure,
where the average inﬂuence for Italian centers is 0.08 and for
Table 1 Per patient costs according to center characteristics:Me (mean,
standard deviation) (25th, 75th percentile)
N Cost
Hospitalizations
Me (12,213) 271 2,923 (7,417, 8,602) [2,223, 11,011]
>Me (12,213) 187 4,967 (8,499, 8,100) [2,450, 12,275]
Cardiac department (N)
= 1 441 3,595 (7,859, 8,408) [2,450, 11,361]
>1 17 4,556 (8,573, 9,006) [2,800, 11,588]
Permanent cardiologist in ER
Absent 353 3,561 (7,843, 8,630) [2,423, 11,361]
Present 105 4,206 (7,911, 7,654) [2,450, 11,405]
Coronary angioplasty unit
Absent 233 3,211 (7,659, 8,172) [2,450, 11,238]
Present 225 4,144 (8,066, 8,660) [2,223, 11,588]
Beds
Me (350) 280 3,564 (8,007, 8,656) [2,450, 11,594]
>Me (350) 178 3,884 (7,181, 7,170) [2,450, 10,600]
Patients admitted in ER
Me (245,00) 236 2,800 (6,686, 8,171) [2,223, 5,956]
>Me (24,500) 179 4,494 (8,376, 8,472) [2,450, 11,711]
Cardiac surgery unit
Absent 349 3,623 (7,968, 8,200) [2,450, 11,613]
Present 109 3,567 (7,509, 9,074) [2,223, 10,244]
Coronary angiography unit
Absent 274 3,150 (7,344, 7,923) [2,450, 11,011]
Present 184 4,559 (8,627, 9,051) [2,280, 11,946]
Hospitalizations in Cardiology
Me (760) 274 3,595 (7,859, 8,408) [2,450, 11,361]
>Me (760) 184 4,559 (8,627, 9,051) [2,280, 11,946]
Myocardial infarction (N)
Me (300) 274 3,966 (8,024, 8,306) [2,280, 11,711]
>Me (300) 184 3,330 (7,489, 8,652) [2,450, 9,161]
Rest echo exams performed
Me (3,653) 299 3,330 (7,405, 7,895) [2,450, 10,981]
>Me (3,653) 159 4,495 (8,714, 9,263) [2,223, 12,353]
Exercise test exams performed
Me (800) 233 4,844 (8,841, 8,923) [2,322, 12,061]
>Me (800) 225 2,923 (7,027, 7,869) [2,450, 10,183]
Transplants performed
= 0 391 3,917 (8,001, 8,186) [2,450, 11,575]
>0 67 2,560 (7,029, 9,633) [2,131, 10,308]
Beds in cardiology
Me (21) 246 4,439 (8,253, 7,972) [2,450, 12,061]
>Me (21) 212 3,150 (7,402, 8,885) [2,265, 10,136]
Beds in Coronary intensive unit
Me (6) 314 3,561 (7,678, 8,236) [2,450, 10,974]
>Me (6) 144 3,911 (8,254, 8,028) [2,276, 11,669]
Hearth failures (N)
Me (100) 231 2,923 (7,347, 8,621) [2,450, 9,628]
>Me (100) 227 4,144 (8,025, 8,344) [2,423, 11,394]
Stress echo exams performed
Me (121) 246 5,194 (8,793, 8,202) [2,450, 12,407]
>Me (121) 212 2,923 (7,102, 8,513) [2,223, 10,017]
PTCA performed
= 0 274 3,150 (7,344, 7,923) [2,450, 11,011]
>0 184 4,559 (8,627, 9,051) [2,280, 11,946]
CABG performed
= 0 349 3,561 (7,753, 8,458) [2,223, 11,011]
>0 109 3,850 (8,200, 8,454) [2,511, 12,411]
ER, emergency room; Me, median; PTCA, percutaneous transluminal coronary angioplasty;
CABG, Coronary artery bypass grafting.
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Turkish centers 0.10, for model M1. For Model M4 the average
inﬂuence for Italian centers is 0.12 and for Turkish centers 0.08,
with the increase in the difference because of the effect of the
General Hospital of San Giovanni Rotondo (Foggia, Italy).
Most of the residual inﬂuence is eventually given by the hetero-
geneity among Italian centers.
Discussion
Finding good predictors of subsequent cost is notoriously difﬁ-
cult, in both health economic evaluations [22] and in insurance
risk assessment. Prior resource use is sometimes the only really
important predictor of subsequent resource use [5]. In most of
Table 2 Gamma and ML Gamma models with log-link estimating the effect of patient variables on total cost: coefﬁcient, standard errors (SE) and
two-sided P-values
No center information
(Gamma model)
Center as random effect
(multilevel Gamma model)
Effect SE P-value Effect SE P-value
(Intercept) 9.03 0.16 0.00 9.03 0.17 0.00
Strategy 1 vs. 2 -0.14 0.10 0.09 -0.17 0.10 0.05
Gender (male vs. female) -0.10 0.14 0.24 -0.10 0.14 0.24
Age >65 vs.65 -0.07 0.12 0.26 -0.04 0.12 0.35
Hypertension (presence vs. absence) 0.20 0.10 0.03 0.22 0.10 0.02
Previous AMI (presence vs. absence) -0.14 0.21 0.25 -0.10 0.21 0.32
Diabetes (presence vs. absence) 0.15 0.14 0.15 0.13 0.14 0.17
t2 0.02 0.13
Within center correlation (95% conﬁdence interval) 0.11 (0.04-0.21)
Table 3 Models with center characteristics, included as ﬁxed effects and random effects, always using a random intercept: coefﬁcient, standard errors
(SE) and two-sided P-values
Center characteristics as ﬁxed effects Center characteristics as random effects
Effect SE P-value Effect SE P-value
(Intercept) 9.07 0.20 0.00 9.06 0.27 0.00
Strategy 1 vs. 2 -0.14 0.10 0.09 -0.18 0.10 0.04
Gender (male vs. female) -0.08 0.14 0.28 -0.10 0.14 0.24
Age >65 vs.65 -0.06 0.12 0.32 -0.03 0.12 0.39
Hypertension (presence vs. absence) 0.20 0.10 0.03 0.22 0.10 0.02
Previous AMI (presence vs. absence) -0.11 0.22 0.30 -0.08 0.22 0.36
Diabetes (presence vs. absence) 0.15 0.14 0.15 0.12 0.14 0.20
Beds in Cardiology Department 0.00 0.00 0.28
Primary PTCA Setting 0.01 0.13 0.47
Number of MI treated -0.01 0.01 0.18
Random effects
Beds in Cardiology Department 0.01 0.01 0.39
Primary PTCA Setting -0.04 0.22 0.43
Number of MI treated -0.01 0.01 0.40
t2 (between center variability) 0.03 0.16 0.04 0.09
Within Center correlation (95% conﬁdence interval) 0.13 (0.05–0.25) 0.09 (0.04–0.22)
AMI, acute myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; MI, myocardial infarction.
Figure 1 Inﬂuence plots. Left panel refers to the marginal model M1, right panel to the marginal model M4. Inﬂuence is the Preisser and Qaqish measure [19].
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the multi-center studies, balance in patient characteristics is
granted by the randomization procedure adopted for the study.
In this study, we indeed observed a high level of homogeneity in
patients’ baseline characteristics in each center. Nevertheless, in
such multicenter studies, patients were assigned at speciﬁed strat-
egies of treatment in each hospital but were treated by different
medical staff. With respect to the between-hospital variability,
the heterogeneity of the hospitals clinical practice seems to be
more signiﬁcant than the patient case-mix one. Overall within-
center correlation was perhaps small, but still inﬂuencing the
estimates, as shown by the changes in effect when different
hierarchical structures are used and different degree of informa-
tion on the center characteristic is put in the model.
Center Effect without Center-Speciﬁc Information
In common situations, no covariates are available to describe the
center selection process, as no control is over the factors contrib-
uting to a center investigator choice to participate in the study. In
this case, the common approach is to model the center effect
using a random intercept in the model [23]. This correction
usually inﬂates standard errors of the estimates of the parameters
which are related to variables describing center characteristics.
This effect can be additionally emphasized by the estimation
procedure adopted, when based on shrinkage. Indeed, the effect
of Strategy 1 is highly dependent on adjustment by center effect,
varying at about 26% (from -0.14 to -0.17). More interestingly,
signiﬁcance of the parameter changes from 0.09 to 0.05, with
consequent important changes in the results interpretation. The
fact that the effect of the strategy is dependent on the proper
modeling of the center is entirely because of the fact that the data
are collected in different sites.
Center Effect with Center-Speciﬁc Information
When information on some characteristics of the centers is avail-
able, further information can be added in the model. First, char-
acteristics of the centers should involve information on activity
levels and on size of the structure. If available, additional infor-
mation on the population referring to the center could also be
helpful, but it is not always the case; second, treating such
information can be accomplished in two ways, by using the
information at center level as ﬁxed effects, or as random effects.
In Table 3 the two approaches are compared. First, it has to be
noticed that the cost reductions attributable to Strategy 1 in the
ﬁnal model are signiﬁcant at 0.05 level. This is a sign that the
efﬁcacy of the strategy is dependent on the center where it is
applied. This is particularly true in a trial setting like the
COSTAMI, where the intervention is essentially focused on the
criteria over patient management and discharge, all being clearly
related to health-care organization.
In the ﬁxed effect model, the idea is that the effect of the
number of myocardial infarction (MI) treated (a possible proxy
for center experience) directly inﬂuences the cost of patient care,
having already discounted for a set of relevant covariates possi-
bly related to expenditure.
Study Limitations
Some limitations of the study must be acknowledged. First, data
were collected within one randomized international multicenter
trial over two countries, and therefore costs in medical care may
differ substantially between participating institutions in different
countries, where differences can be attributable to the different
health-care systems and incentives, and differences in reimburse-
ment mechanisms at the national or local level. Second, although
the set of variables collected for describing the center character-
istics covers a sensitive range of issues for what concerns the
patients’ management, still they are not exhausting all possible
information. This may result in a bias of the analysis, which can
be reduced only partially by the inclusion of a latent variable
trying to capture unmeasured center characteristics. Our analysis
relies on estimates of resource use from patients in all countries
(fully pooled) and use a one-country costing approach, applying
unit cost estimates from one country to resource use in all coun-
tries [4]. In this way, patient-level relationship between use of
resources and costs are not maintained. The impact of this
method may depend on the differences in costs and use of
resources between centers in the different countries. Neverthe-
less, because of the observed distribution of centers in the differ-
ent countries (eight from Italy and two from Turkey), to
explicitly consider the country effect in the same model with the
center was not advisable, given the (in one case complete) alias-
ing between center and country.
Second, in the estimation of the use of resources we apply a
low-cost approach which considers only the major relevant
sources of cost during 1-year follow-up and not the full cost of
care.
Finally, the impact of center variables on outcome estimates
has been evaluated with reference to a real trial, limiting results
generalizability to other situations. Nevertheless, this is the ﬁrst
contribution which has not used results based on simulation or
theoretical arguments.
Final Remarks
This study, with reference to a real multi-center trial on costs of
treatment of AMI, and using best ﬁtting Gamma models, shows
that center information cannot be neglected and should be col-
lected and inserted in the analysis, better in combination with
latent variables, in order to capture also the heterogeneity
between centers because of unobserved centers characteristics.
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